{"id":1937,"date":"2024-05-21T21:30:23","date_gmt":"2024-05-22T01:30:23","guid":{"rendered":"https:\/\/9bio.ca\/?p=1937"},"modified":"2026-01-20T09:25:24","modified_gmt":"2026-01-20T14:25:24","slug":"9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator","status":"publish","type":"post","link":"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\/","title":{"rendered":"9Bio Th\u00e9rapeutiques rejoint l\u2019Acc\u00e9l\u00e9rateur National de Th\u00e9rapeutiques d\u2019adMare BioInnovations"},"content":{"rendered":"<p><strong>Qu\u00e9bec, le 21 mai 2024<\/strong> \u2013 9Bio Th\u00e9rapeutiques, une entreprise biotechnologique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de th\u00e9rapies oncologiques de nouvelle g\u00e9n\u00e9ration, est fi\u00e8re d\u2019annoncer son int\u00e9gration \u00e0 l\u2019Acc\u00e9l\u00e9rateur National de Th\u00e9rapeutiques (Tx) d\u2019adMare BioInnovations. Ce partenariat strat\u00e9gique vise \u00e0 faire progresser la mission de 9Bio : d\u00e9velopper des th\u00e9rapies cibl\u00e9es contre le cancer, ax\u00e9es sur la s\u00e9curit\u00e9 des patients et l\u2019efficacit\u00e9 des traitements.<\/p>\n\n\n\n<p>L\u2019approche innovante de 9Bio repose sur une plateforme propri\u00e9taire de biologie structurale assist\u00e9e par l\u2019IA, int\u00e9grant des contextes anatomiques et biochimiques. Cette technologie permet de concevoir des m\u00e9dicaments ciblant s\u00e9lectivement les cellules tumorales tout en minimisant l\u2019impact sur les tissus sains. Actuellement, le portefeuille de 9Bio comprend trois th\u00e9rapies en phase de d\u00e9couverte, chacune offrant un potentiel prometteur pour le traitement du cancer.<\/p>\n\n\n\n<p>\u00ab Rejoindre l\u2019Acc\u00e9l\u00e9rateur National Tx d\u2019adMare est une \u00e9tape importante pour 9Bio<em>,<\/em>\u00bb, a d\u00e9clar\u00e9 Henrique De Carvalho, PDG et cofondateur de 9Bio Therapeutics. \u00ab Cette collaboration nous apporte des ressources et une expertise pr\u00e9cieuses pour acc\u00e9l\u00e9rer le d\u00e9veloppement de nos th\u00e9rapies et nous rapprocher de solutions innovantes pour les patients atteints de cancer. \u00bb<\/p>\n\n\n\n<p>L\u2019Acc\u00e9l\u00e9rateur Tx national d\u2019adMare accompagne de jeunes entreprises canadiennes impliqu\u00e9es dans le d\u00e9veloppement de nouvelles th\u00e9rapies. Il apporte des conseils scientifiques, juridique, li\u00e9 \u00e0 la propri\u00e9t\u00e9 intellectuelle, en mati\u00e8re de d\u00e9veloppement commercial, ainsi qu\u2019un soutien pour la strat\u00e9gie de lever de fonds et l\u2019acc\u00e8s au r\u00e9seau professionnel d\u2019adMare. Ce programme personnalis\u00e9 aide les start-ups comme 9Bio \u00e0 franchir les \u00e9tapes essentielles du d\u00e9veloppement et de la commercialisation de nouvelles th\u00e9rapies au Canada.<\/p>\n\n\n\n<p>\u00ab Nous sommes ravis d\u2019accueillir 9Bio au sein de notre Acc\u00e9l\u00e9rateur \u00bb, a d\u00e9clar\u00e9 Clara Ducord, Responsable de l\u2019Acc\u00e9l\u00e9rateur National Tx. \u00ab Notre objectif est d\u2019aider ces entreprises \u00e0 innover et \u00e0 se d\u00e9velopper. En travaillant avec nos partenaires du secteur, nous esp\u00e9rons contribuer aux avanc\u00e9es en sciences de la vie et \u00e0 la cr\u00e9ation d\u2019opportunit\u00e9s \u00e9conomiques de grande valeur \u00e0 l\u2019\u00e9chelle nationale. \u00bb<\/p>\n\n\n\n<p class=\"has-theme-palette-9-color has-text-color has-link-color wp-elements-d640300c7a5c946b81fffdd7a5db2c1d\">Cliquez <a href=\"https:\/\/www.admarebio.com\/fr\/actualites-details\/admare-bioinnovations-accueille-cinq-nouvelles-start-ups-au-sein-de-laccelerateur-tx-national\" target=\"_blank\" rel=\"noreferrer noopener\">ici<\/a> pour lire l\u2019annonce officielle d\u2019adMare BioInnovations.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>\u00c0 propos de 9Bio Th\u00e9rapeutiques<\/strong><\/p>\n\n\n\n<p>9Bio est une entreprise de biotechnologie d\u00e9di\u00e9e au d\u00e9veloppement de th\u00e9rapies oncologiques innovantes. Notre plateforme de biologie structurale guid\u00e9e par l'IA int\u00e8gre des contextes anatomiques et biochimiques pour concevoir des m\u00e9dicaments ciblant s\u00e9lectivement les tumeurs. Gr\u00e2ce \u00e0 cette approche, nous d\u00e9veloppons des traitements sp\u00e9cifiquement dirig\u00e9s contre les tumeurs, tout en pr\u00e9servant les tissus sains, am\u00e9liorant ainsi la s\u00e9curit\u00e9, l\u2019efficacit\u00e9 et ouvrant la voie \u00e0 des modalit\u00e9s th\u00e9rapeutiques jusqu\u2019ici sous-exploit\u00e9es. Notre pipeline comprend deux th\u00e9rapies en phase de d\u00e9couverte : un conjugu\u00e9 anticorps-m\u00e9dicament (ADC) ciblant les cellules tumorales chimior\u00e9sistantes et un autre ADC ciblant les cellules immunitaires subverties par les tumeurs.<\/p>\n\n\n\n<p><strong>\u00c0 propos d\u2019adMare BioInnovations<\/strong><\/p>\n\n\n\n<p class=\"has-theme-palette-9-color has-text-color has-link-color wp-elements-7c5d4591f9f5f10f24a76147a787dad3\">Avec une multitude de d\u00e9couvertes scientifiques concurrentielles sur la sc\u00e8ne mondiale, le Canada est pr\u00eat \u00e0 devenir un chef de file dans le domaine des sciences de la vie. Pour que cela se concr\u00e9tise, chez adMare BioInnovations, nous utilisons notre expertise scientifique, notre savoir-faire commercial, notre infrastructure de recherche et d\u00e9veloppement sp\u00e9cialis\u00e9e, ainsi que des capitaux de d\u00e9marrage afin de mettre sur pied de solides compagnies du secteur des sciences de la vie, cr\u00e9er des \u00e9cosyst\u00e8mes robustes et d\u00e9velopper des talents adapt\u00e9s aux besoins de l\u2019industrie. Nous r\u00e9investissons \u00e9galement nos revenus dans l\u2019industrie canadienne afin d\u2019en assurer la p\u00e9rennit\u00e9. adMare compte actuellement 29 soci\u00e9t\u00e9s de portefeuille qui ont attir\u00e9 plus de 2,3 milliards de dollars en capital-risque, ont une valeur combin\u00e9e de plus de 4\u202fmilliards de dollars, et ont permis de cr\u00e9er plus de 1000 emplois au Canada. Pour plus d\u2019information, veuillez consulter le <a href=\"http:\/\/www.admarebio.com\" target=\"_blank\" rel=\"noreferrer noopener\">www.admarebio.com<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>9Bio Th\u00e9rapeutiques est fi\u00e8re d\u2019annoncer son int\u00e9gration \u00e0 l\u2019Acc\u00e9l\u00e9rateur National de Th\u00e9rapeutiques (Tx) d\u2019adMare BioInnovations. Ce partenariat strat\u00e9gique vise \u00e0 faire progresser la mission de 9Bio : d\u00e9velopper des th\u00e9rapies cibl\u00e9es contre le cancer, ax\u00e9es sur la s\u00e9curit\u00e9 des patients et l\u2019efficacit\u00e9 des traitements.<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":[],"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueState":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_VenueShowMap":false,"_VenueShowMapLink":false,"_kadence_starter_templates_imported_post":false,"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-1937","post","type-post","status-publish","format-standard","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>9Bio Therapeutics joins adMare BioInnovations&#039; National Therapeutics Accelerator - 9Bio Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"9Bio Therapeutics joins adMare BioInnovations&#039; National Therapeutics Accelerator - 9Bio Therapeutics\" \/>\n<meta property=\"og:description\" content=\"9Bio Therapeutics is proud to announce its acceptance into the adMare BioInnovations National Therapeutics (Tx) Accelerator. This strategic partnership aims to advance 9Bio&#039;s mission of developing targeted cancer therapies that prioritize patient safety and treatment efficacy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\/\" \/>\n<meta property=\"og:site_name\" content=\"9Bio Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-22T01:30:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-20T14:25:24+00:00\" \/>\n<meta name=\"author\" content=\"Henrique de Carvalho\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Henrique de Carvalho\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\\\/\"},\"author\":{\"name\":\"Henrique de Carvalho\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/person\\\/eda3764256a793b2350112b46b0169a8\"},\"headline\":\"9Bio Therapeutics joins adMare BioInnovations&#8217; National Therapeutics Accelerator\",\"datePublished\":\"2024-05-22T01:30:23+00:00\",\"dateModified\":\"2026-01-20T14:25:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\\\/\"},\"wordCount\":453,\"publisher\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"fr-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\\\/\",\"url\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\\\/\",\"name\":\"9Bio Therapeutics joins adMare BioInnovations' National Therapeutics Accelerator - 9Bio Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#website\"},\"datePublished\":\"2024-05-22T01:30:23+00:00\",\"dateModified\":\"2026-01-20T14:25:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/9biotx.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"9Bio Therapeutics joins adMare BioInnovations&#8217; National Therapeutics Accelerator\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#website\",\"url\":\"https:\\\/\\\/9biotx.com\\\/\",\"name\":\"9Bio Therapeutics\",\"description\":\"Engineering Biological Possibilities\",\"publisher\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/9biotx.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\",\"name\":\"9Bio Therapeutics\",\"url\":\"https:\\\/\\\/9biotx.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/9biotx.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/9Bio-therapeutics-transparent-background-tangerine-small.png\",\"contentUrl\":\"https:\\\/\\\/9biotx.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/9Bio-therapeutics-transparent-background-tangerine-small.png\",\"width\":200,\"height\":80,\"caption\":\"9Bio Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/9bio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/person\\\/eda3764256a793b2350112b46b0169a8\",\"name\":\"Henrique de Carvalho\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"caption\":\"Henrique de Carvalho\"},\"sameAs\":[\"https:\\\/\\\/9bio.ca\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"9Bio Therapeutics joins adMare BioInnovations' National Therapeutics Accelerator - 9Bio Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\/","og_locale":"fr_CA","og_type":"article","og_title":"9Bio Therapeutics joins adMare BioInnovations' National Therapeutics Accelerator - 9Bio Therapeutics","og_description":"9Bio Therapeutics is proud to announce its acceptance into the adMare BioInnovations National Therapeutics (Tx) Accelerator. This strategic partnership aims to advance 9Bio's mission of developing targeted cancer therapies that prioritize patient safety and treatment efficacy.","og_url":"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\/","og_site_name":"9Bio Therapeutics","article_published_time":"2024-05-22T01:30:23+00:00","article_modified_time":"2026-01-20T14:25:24+00:00","author":"Henrique de Carvalho","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Henrique de Carvalho","Estimation du temps de lecture":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\/#article","isPartOf":{"@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\/"},"author":{"name":"Henrique de Carvalho","@id":"https:\/\/9biotx.com\/#\/schema\/person\/eda3764256a793b2350112b46b0169a8"},"headline":"9Bio Therapeutics joins adMare BioInnovations&#8217; National Therapeutics Accelerator","datePublished":"2024-05-22T01:30:23+00:00","dateModified":"2026-01-20T14:25:24+00:00","mainEntityOfPage":{"@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\/"},"wordCount":453,"publisher":{"@id":"https:\/\/9biotx.com\/#organization"},"articleSection":["News"],"inLanguage":"fr-CA"},{"@type":"WebPage","@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\/","url":"https:\/\/9biotx.com\/news\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\/","name":"9Bio Therapeutics joins adMare BioInnovations' National Therapeutics Accelerator - 9Bio Therapeutics","isPartOf":{"@id":"https:\/\/9biotx.com\/#website"},"datePublished":"2024-05-22T01:30:23+00:00","dateModified":"2026-01-20T14:25:24+00:00","breadcrumb":{"@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/9biotx.com\/news\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/9biotx.com\/"},{"@type":"ListItem","position":2,"name":"9Bio Therapeutics joins adMare BioInnovations&#8217; National Therapeutics Accelerator"}]},{"@type":"WebSite","@id":"https:\/\/9biotx.com\/#website","url":"https:\/\/9biotx.com\/","name":"9Bio Th\u00e9rapeutiques","description":"Engineering Biological Possibilities","publisher":{"@id":"https:\/\/9biotx.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/9biotx.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/9biotx.com\/#organization","name":"9Bio Th\u00e9rapeutiques","url":"https:\/\/9biotx.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/9biotx.com\/#\/schema\/logo\/image\/","url":"https:\/\/9biotx.com\/wp-content\/uploads\/2024\/10\/9Bio-therapeutics-transparent-background-tangerine-small.png","contentUrl":"https:\/\/9biotx.com\/wp-content\/uploads\/2024\/10\/9Bio-therapeutics-transparent-background-tangerine-small.png","width":200,"height":80,"caption":"9Bio Therapeutics"},"image":{"@id":"https:\/\/9biotx.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/9bio\/"]},{"@type":"Person","@id":"https:\/\/9biotx.com\/#\/schema\/person\/eda3764256a793b2350112b46b0169a8","name":"Henrique de Carvalho","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","caption":"Henrique de Carvalho"},"sameAs":["https:\/\/9bio.ca"]}]}},"taxonomy_info":{"category":[{"value":1,"label":"News"}]},"featured_image_src_large":false,"author_info":{"display_name":"Henrique de Carvalho","author_link":"https:\/\/9biotx.com\/fr\/news\/author\/decarvalho\/"},"comment_info":1,"category_info":[{"term_id":1,"name":"News","slug":"news","term_group":0,"term_taxonomy_id":1,"taxonomy":"category","description":"9Bio News","parent":0,"count":7,"filter":"raw","cat_ID":1,"category_count":7,"category_description":"9Bio News","cat_name":"News","category_nicename":"news","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/1937","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/comments?post=1937"}],"version-history":[{"count":5,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/1937\/revisions"}],"predecessor-version":[{"id":1993,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/1937\/revisions\/1993"}],"wp:attachment":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/media?parent=1937"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/categories?post=1937"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/tags?post=1937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}